文献速递中医内科中药与中成药合理使用

益气活血方治疗缺血性卒中气虚血瘀证的随机对照试验研究方案

Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial.
PubMed 文献 · Front Pharmacol · 2020-06-17

本研究为多中心、随机、双盲、安慰剂对照试验,拟纳入160例缺血性卒中气虚血瘀证患者,随机分配至补阳还五颗粒、脑心通胶囊、养阴通脑颗粒或安慰剂组(1:2:1:1),治疗28天并随访180天,主要结局为NIHSS评分变化,旨在评估方证相关度并寻找相关生物标志物。

要点

  • 比较三种益气活血类中成药在缺血性卒中气虚血瘀证患者中的方证相关度。
  • 主要结局为用药28天后NIHSS评分变化,次要结局包括mRS、ADL及中医症状评分。
  • 试验采用多中心、随机、双盲、安慰剂对照设计,样本量160例。

核心结论

  • 试验旨在评估补阳还五颗粒、脑心通胶囊和养阴通脑颗粒在缺血性卒中气虚血瘀证患者中的方证相关度水平,并寻找相关生物标志物,为中医精准治疗提供客观依据。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照干预试验,拟纳入160例缺血性卒中气虚血瘀证患者。
  • 受试者按1:2:1:1比例随机分配至补阳还五颗粒组、脑心通胶囊组、养阴通脑颗粒组和安慰剂组。
  • 所有受试者接受28天治疗,随后随访180天。

关键数值与推荐

  • 主要结局为用药28天后美国国立卫生研究院卒中量表(NIHSS)评分的变化。
  • 次要结局包括改良Rankin量表(mRS)评分、日常生活活动能力量表(ADL)评分和中医症状评分。
  • 试验已获浙江中医药大学附属第一医院研究伦理委员会批准(ID: 2017-Y-004-02),并在中国临床试验注册中心注册(ChiCTR1800015189)。

临床怎么用

  • 该试验结果将为缺血性卒中气虚血瘀证患者使用益气活血类中成药(补阳还五颗粒、脑心通胶囊、养阴通脑颗粒)的精准选择提供循证依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ischemic stroke (IS) is characterized by high morbidity and high mortality. The integration of Traditional Chinese medicine (TCM) and western medicine has shown promising benefits in relieving symptoms, promoting neurological recovery, and improving the quality of life of patients with IS. In TCM, Qi-deficiency along with blood-stasis (QDBS) syndrome is one of the common types of IS that is treated by invigorating Qi and activating blood circulation. In TCM theory, improving the corresponding degree of prescription-syndrome correlation (PSC) is helpful to improve clinical efficacy. In this study, we intend to use similar prescriptions that invigorate Qi and activate blood circulation: Buyang Huanwu granules (BHG), Naoxintong capsules (NXTC), and Yangyin Tongnao granules (YTG). The goal is to evaluate their level of PSC inpatients with IS with QDBS syndrome and find relevant biomarkers to provide an objective basis for precise treatment of TCM and improve the clinical therapeutic effects. A multicenter, randomized, double-blinded, and placebo-controlled intervention trial will be conducted in IS patients with QDBS syndrome, followed by an add-on of Chinese patent medicine. A total of 160 subjects will be randomly assigned to the BHG, NXTC, YTG, and placebo groups in a 1:2:1:1 allocation ratio. All subjects will undergo 28 days of treatment and then followed for another 180 days. The primary outcome is the changes in the National Institutes of Health Stroke Scale score after 28 days of medication. The secondary outcomes include the modified Rankin scale score, activity of daily living scale score, and TCM symptom score. Data will be analyzed in accordance with a predefined statistical analysis plan. Ethical approval of this trial has been granted by the Research Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (ID: 2017-Y-004-02). Written informed consent of patients will be required. This trial is registered in the Chinese Clinical Trial Registry (ChiCTR1800015189), and the results will be disseminated to the public through peer-reviewed journals and academic conferences.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Zhang L, Pan YJ, et al. Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial. Front Pharmacol. 2020. PMID: 32625091. doi:10.3389/fphar.2020.00892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。